Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: February 3, 2026
Context: Announcement of full-year 2025 results and full-year 2026 sales and operating profit outlook at constant exchange rates (CER). The company is introducing new non-IFRS measures ("adjusted sales" and "adjusted operating profit") to exclude exceptional, non-recurring effects, primarily related to the 340B Drug Pricing Program.
Key Financial Metrics
2025 Full-Year Performance (CER)
- Sales Growth: 10% (vs. prior guidance of 8% to 11%).
- Operating Profit (EBIT) Growth: 6% (vs. prior guidance of 4% to 7%).
- Q4 2025 Performance: Sales growth of -2%; Operating profit growth of -4%.
- US Operations: Positively impacted by gross-to-net sales adjustments in 2025.
2026 Full-Year Outlook (CER)
- Adjusted Sales Growth: -5% to -13%.
- Adjusted Operating Profit Growth: -5% to -13%.
- Non-Adjusted Mid-Point Guidance: Sales growth of -1%; Operating profit growth of 11%.
- Key Adjustment: A reversal of sales rebate provisions of USD 4.2 billion related to the 340B Drug Pricing Program is excluded from the "adjusted" figures but included in the "non-adjusted" figures.
Material Changes and Drivers
- 340B Reversal: A significant one-time positive impact of USD 4.2 billion in 2026 (compared to USD 400 million in 2025) related to the 340B Drug Pricing Program reversal. This drives the divergence between adjusted and non-adjusted guidance.
- US Operations Decline: Expected sales decline in 2026 due to the MFN ("Most Favoured Nations") agreement with the US Administration, reduced Medicaid coverage for obesity medications, and the absence of 2025 gross-to-net adjustments.
- International Operations: Growth expected to continue but tempered by intensifying competition and the loss of exclusivity for the semaglutide molecule in certain markets.
- Product Mix: Outlook includes the January 2026 launch of the Wegovy pill, with assumptions regarding market penetration and potential cannibalization of injectable sales.
- FX Impact: Adjusted sales growth in Danish kroner is expected to be 3 percentage points lower than CER due to USD/DKK depreciation.
Guidance, Outlook, and Risks
Management Commentary
Management emphasizes that the "adjusted" metrics provide a clearer view of underlying operating performance by stripping out non-cash, non-recurring items. The outlook assumes continued global GLP-1 market expansion and volume growth, countered by lower realized prices and patent expiries.
Investments and Strategy
- R&D: Continued investment in the Obesity and Diabetes pipeline, including the impact of the Akero Therapeutics, Inc. acquisition.
- Commercial: Focus on expanding access to Wegovy via the self-pay channel (NovoCare Pharmacy) and telehealth collaborations.
- Cost Optimization: Investments partly funded by savings from the 2025 company-wide transformation.
Risks and Contingencies
- Legal Matters: Potential future exclusions for major legal matters or impairment losses from adjusted operating profit.
- Competition: Intensifying competition in both US and International markets.
- Regulatory/Pricing: Impact of the MFN agreement and Medicaid coverage changes on US pricing.
Investor Verification Checklist
- Verify the specific accounting treatment and timing of the USD 4.2 billion 340B rebate provision reversal in the full 2025 financial report.
- Confirm the detailed assumptions regarding the market penetration and cannibalization effects of the Wegovy pill launch in Q1 2026.
- Review the full disclosure of the new non-IFRS measures ("adjusted sales" and "adjusted operating profit") to understand the reconciliation to GAAP/IFRS figures.
- Monitor the impact of the MFN agreement on realized prices in the US market throughout 2026.
- Assess the timeline and financial impact of the semaglutide compound patent expiry in key international markets.